<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569307</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-NAYAB-001</org_study_id>
    <nct_id>NCT02569307</nct_id>
  </id_info>
  <brief_title>Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States</brief_title>
  <acronym>NAYAB</acronym>
  <official_title>A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo controlled trial which aims to evaluate the&#xD;
      efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS.&#xD;
      Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to&#xD;
      Treatment as Usual in an operationalized ARMS population in Pakistan:&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hypothesis is that the persons with ARMS who are prescribed minocycline and / or&#xD;
      Omega-3 fatty acids will have reduced transition rates to psychosis over a one year follow up&#xD;
      period (from baseline) compared with Treatment-As-Usual (TAU). The transition rates will be&#xD;
      lowest in the group receiving minocycline and Omega-3 fatty acids in combination.&#xD;
&#xD;
      Secondary objective is to determine that the Persons with ARMS who are prescribed minocycline&#xD;
      and / or Omega-3fatty acids in combination will have greatest symptom reduction compared with&#xD;
      TAU.&#xD;
&#xD;
      This study will be a six-month intervention of minocycline and/or Omega-3 fatty acids added&#xD;
      to TAU in patients with ARMS, using a randomised, placebo-controlled, double-blind factorial&#xD;
      design.The study will be a four-arm trial: one arm will receive minocycline with TAU; the&#xD;
      second arm will receive Omega-3 fatty acids with TAU; the third arm will receive both&#xD;
      minocycline and Omega-3 fatty acids with TAU; the fourth arm will receive placebo with TAU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transition to psychotic disorder</measure>
    <time_frame>12 Months</time_frame>
    <description>Structure Clinical interview for DSM-IV(SCID) (Michael B et al,. 2002) to confirm the transition to psychosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured severity ofAt Risk of Mental State ( ARMS) symptoms</measure>
    <time_frame>12 Months</time_frame>
    <description>Comprehensive Assessment of At-Risk Mental States (CAARMS) (Berger, GEet al2006).A semi-structured interview that assists in the identification of individuals at risk of developing a first-episode psychotic disorder and measured the severity of ARMS symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>At Risk Mental State (ARMS)</condition>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline added to TAU Minocycline will be administered in 200mg once daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo added to TAU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline Plus Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline added to TAU Minocycline will be administered in 200mg once daily dose</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose</description>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo added to TAU</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline Plus Omega-3 fatty acids</intervention_name>
    <description>Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose</description>
    <arm_group_label>Minocycline Plus Omega-3 fatty acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female help seeking individuals aged between 16-35 years.&#xD;
&#xD;
          2. Meets at least one of the criteria for ARMS (see CAARMS Operationalized Intake&#xD;
             Criteria section below).&#xD;
&#xD;
          3. Assessed as competent to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History ofpreviously experiencing a psychotic illness (treated or untreated).&#xD;
&#xD;
          2. IQ &lt; 70 and/or history of learning disability.&#xD;
&#xD;
          3. Any pre-existing inflammatory conditions e.g. rheumatoid arthritis.&#xD;
&#xD;
          4. Organic brain disease e.g. epilepsy.&#xD;
&#xD;
          5. treatment with an antipsychotic or mood-stabilising agent.&#xD;
&#xD;
          6. Prior history of intolerance or serious side effects (hepatotoxicity,&#xD;
             photosensitivity, blood dyscrasias) to any of the tetracyclines or Omega-3 fatty&#xD;
             acids.&#xD;
&#xD;
          7. Concomitant penicillin therapy or concomitant anticoagulant therapy.&#xD;
&#xD;
          8. Active substance abuse (except nicotine or caffeine) or dependence within the last&#xD;
             three months, according to DSM-V criteria.&#xD;
&#xD;
          9. Treatment with warfarin or lamotrigine.&#xD;
&#xD;
         10. Current or previous treatment with tetracycline antibiotics or Omega-3 fatty acids in&#xD;
             the preceding three months before study entry.&#xD;
&#xD;
         11. Current treatment with any anti-inflammatory medication.&#xD;
&#xD;
         12. Treatment with electroconvulsive therapy within the 12 weeks preceding the study.&#xD;
&#xD;
         13. Active expression of suicidal ideation (CAARMS item 7.3 severity score 6) or current&#xD;
             aggression/dangerous behaviour (CAARMS item 5.4 severity score 6). 14. Relevant&#xD;
             current or past hematologic, hepatic, renal, neurological or other medical disorder&#xD;
             that in the opinion of the principal investigator may interfere with the study.&#xD;
&#xD;
        15. Pregnant or breastfeeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Inti Qurashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester University ,UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civil hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karwn e Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colleges and Universities</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practitioners (GPs)</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Behavioral Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://pill.org.pk</url>
    <description>Website of Pakistan Institute of Learning and Living</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>At Risk of Mental State</keyword>
  <keyword>Prodromal Phase</keyword>
  <keyword>Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

